Taken together, the collective evidence strongly supports the notion that GPER1-mediated the activation of cAMP-PKA–dependent AMPK signaling pathway can effectively impede the progression of NAFLD/NASH. The gene discussed is PRKAA2; the disease is metabolic dysfunction-associated steatohepatitis.